All Stories

  1. Delphi consensus guidelines for the use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy for the diagnosis of dementia and mild cognitive impairment with Lewy bodies
  2. The evolving therapeutic landscape of dementia with Lewy bodies
  3. Blood‐derived patterns of inflammation across neurodegenerative diseases
  4. Longitudinal Studies of Blood‐Based Biomarkers for Dementia in Primary Care: A Systematic Review and Meta‐Analysis
  5. Immune Profiling in Early Cognitive Disorders (IMPRINT) study protocol: a longitudinal cohort study exploring biomarkers of inflammation in early dementia with Lewy bodies and Alzheimer’s disease, as part of the Dementias Platform UK
  6. Interrogating DNA methylation associated with Lewy body pathology in a cross brain-region and multi-cohort study
  7. Novel blood‐based proteomic signatures across multiple neurodegenerative diseases
  8. Polygenic risk discriminates Lewy body dementia from Alzheimer's disease
  9. Inflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy
  10. Novel blood-based proteomic signatures across multiple neurodegenerative diseases
  11. From glia to cytokine signatures across the Alzheimer's spectrum
  12. Peripheral innate immunophenotype in neurodegenerative disease: blood-based profiles and links to survival
  13. Blood inflammation relates to neuroinflammation and survival in frontotemporal lobar degeneration
  14. Neuroimaging and Clinical Findings in Healthy Middle-Aged Adults With Mild Traumatic Brain Injury in the PREVENT Dementia Study
  15. The criteria used to rule out mild cognitive impairment impact dementia incidence rates in subjective cognitive decline
  16. Peripheral inflammatory markers relate to central inflammation and survival in syndromes associated with frontotemporal lobar degeneration
  17. Peripheral innate immunophenotype in neurodegenerative disease: blood-based profiles and links to survival
  18. Plasma metabolites distinguish dementia with Lewy bodies from Alzheimer’s disease: a cross-sectional metabolomic analysis
  19. APOE ɛ4 exacerbates age-dependent deficits in cortical microstructure
  20. Inflammation blood profiles across neurodegenerative diseases
  21. Peripheral and central markers of inflammation increased in frontotemporal dementia and related conditions
  22. Peripheral and central markers of inflammation increased in frontotemporal dementia and related conditions
  23. Elucidating distinct molecular signatures of Lewy body dementias
  24. The use of neuroimaging techniques in the early and differential diagnosis of dementia
  25. From protein biomarkers to proteomics in dementia with Lewy Bodies
  26. RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus
  27. The promise of amplification assays for accurate early detection of α-synucleinopathies: A review
  28. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy
  29. In vivo neuroinflammation and cerebral small vessel disease in mild cognitive impairment and Alzheimer’s disease
  30. Epigenetic regulation in the pathophysiology of Lewy body dementia
  31. Efficacy of a dementia intensive support (DIS) service at preventing admissions to medical and psychiatric wards: qualitative and quantitative evaluation
  32. Peak Width of Skeletonized Mean Diffusivity as a Marker of Diffuse Cerebrovascular Damage
  33. Asymmetrical atrophy of thalamic subnuclei in Alzheimer's disease and amyloid‐positive mild cognitive impairment is associated with key clinical features
  34. P2‐373: ASYMMETRICAL THALAMIC SUBNUCLEI IN ALZHEIMER'S DISEASE ASSOCIATED WITH GREATER DISEASE SEVERITY
  35. Age-related disturbances in DNA (hydroxy)methylation in APP/PS1 mice
  36. Peripheral DNA methylation, cognitive decline and brain aging: pilot findings from the Whitehall II imaging study
  37. High dose rivastigmine in the symptom management of Lewy body dementia
  38. Increased 5-hydroxymethylation levels in the sub ventricular zone of the Alzheimer's brain
  39. DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts
  40. Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain
  41. Considering the senses in the diagnosis and management of dementia
  42. Prescribing selective serotonin reuptake inhibitors in older age
  43. S.11.01 Epigenetics in ageing and Alzheimer's disease
  44. Histone Deacetylase 2 in the Mouse Hippocampus: Attenuation of Age- Related Increase by Caloric Restriction
  45. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients
  46. Reduced RAN Expression and Disrupted Transport between Cytoplasm and Nucleus; A Key Event in Alzheimer’s Disease Pathophysiology
  47. Behavioral and neurobiological effects of prenatal stress exposure in male and female APPswe/PS1dE9 mice
  48. Prevention of age-related changes in hippocampal levels of 5-methylcytidine by caloric restriction
  49. Age-Related Increase in Levels of 5-Hydroxymethylcytosine in Mouse Hippocampus is Prevented by Caloric Restriction
  50. The Role of 5-Hydroxymethylcytosine in Aging and Alzheimer’s Disease: Current Status and Prospects for Future Studies
  51. High frequency stimulation of the subthalamic nucleus increases c-fos immunoreactivity in the dorsal raphe nucleus and afferent brain regions
  52. Caloric restriction attenuates age-related changes of DNA methyltransferase 3a in mouse hippocampus
  53. Epigenetic regulation in the pathophysiology of Alzheimer's disease
  54. Gene-Environment Interaction Research and Transgenic Mouse Models of Alzheimer's Disease (Erratum)
  55. Gene-Environment Interaction Research and Transgenic Mouse Models of Alzheimer's Disease